Clinical effect of intra-arterial tumor necrosis factor-α for malignant glioma

Authors:
  • TWToshihiko Wakabayashi
    Toshihiko Wakabayashi
  • MMMasaaki Mizuno
    Masaaki Mizuno
  • KSKenichiro Sugita
    Kenichiro Sugita
  • TYTazuka Yoshida
    Tazuka Yoshida
  • SHShigeaki Hori
    Shigeaki Hori
  • TMTeruaki Mori
    Teruaki Mori
  • TSTomohiko Sato
    Tomohiko Sato
  • AKAtsushi Karashima
    Atsushi Karashima
  • KKKaoru Kurisu
    Kaoru Kurisu
  • KKKatsuzo Kiya
    Katsuzo Kiya
  • TUTohru Uozumi
    Tohru Uozumi
Publisher website
Google Scholar
Abstract
✓ Recombinant human tumor necrosis factor-α was administered intra-arterially to treat 20 cases of malignant gliomas, mostly progressive or recurrent. The optimum dosage was determined to be 1 × 105 U/sq m/day. Among the 10 evaluable patients treated at this dosage, two responded (one completely and one partially), resulting in a 20% response rate. Side effects were mild and easily controllable. Improvement of neurological symptoms was noted in 47% of the patients a few days after treatment, even when computerized tomography showed no tumor regression. This might have been due to the pleiotypic biological activity of tumor necrosis factor-α. Neuroradiographic observations revealed narrowing of the tumor-feeding artery, a decrease in tumor staining ability, and necrosis in the central part of a tumor. The authors suggest that intra-arterial administration of tumor necrosis factor-α may be an effective treatment for malignant glioma, including recurrent cases.

This publication has 26 references indexed in Scilit: